ArticleCell proliferation2007
Directed engineering of umbilical cord blood stem cells to produce C-peptide and insulin.
Article in Cell proliferation, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 79 citations in OpenAlex.
- Fresh autologous blood transfusion reverses erythrocyte damage by reducing oxidative stress via promoting mitochondrial metabolism and M2 macrophage polarization.Archives of medical science : AMS · 2025Article
- Advanced therapy to cure diabetes: mission impossible is now possible?Frontiers in cell and developmental biology · 2024Review
- The effects of stem cells on burn wounds: a review.International journal of burns and trauma · 2019Review
- Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells into Insulin-Producing Cells: Evidence for Further Maturation In Vivo.BioMed research international · 2015Article
- Different Tissue-Derived Stem Cells: A Comparison of Neural Differentiation Capability.PloS one · 2015Article
- In Vitro Differentiation of Human Umbilical Cord Blood CD133(+)Cells into Insulin Producing Cells in Co-Culture with Rat Pancreatic Mesenchymal Stem Cells.Cell journal · 2015Article
- Generation of insulin-producing cells from human bone marrow-derived mesenchymal stem cells: comparison of three differentiation protocols.BioMed research international · 2014Article
- In vitro modelling of cortical neurogenesis by sequential induction of human umbilical cord blood stem cells.Stem cell reviews and reports · 2012Article
- Immunological applications of stem cells in type 1 diabetes.Endocrine reviews · 2011Review
- Stem Cell Therapy: A New Treatment for Burns?Pharmaceuticals (Basel, Switzerland) · 2011Review
- Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes.Stem cell reviews and reports · 2011Review
- The umbilical cord: a rich and ethical stem cell source to advance regenerative medicine.Cell proliferation · 2011Review
- The CD34 surface antigen is restricted to glucagon-expressing cells in the early developing bovine pancreas.Histochemistry and cell biology · 2011Article
- The cord blood separation league table: a comparison of the major clinical grade harvesting techniques for cord blood stem cells.International journal of stem cells · 2010Article
- Stem cell therapy for type 1 diabetes mellitus.Nature reviews. Endocrinology · 2010Review
- Promising new sources for pluripotent stem cells.Stem cell reviews and reports · 2010Review
- The rationale behind collecting umbilical cord blood.Journal of the Turkish German Gynecological Association · 2010Review
- Autologous umbilical cord blood transfusion in very young children with type 1 diabetes.Diabetes care · 2009Article
- Oct-4A isoform is expressed in human cord blood-derived CD133 stem cells and differentiated progeny.Cell proliferation · 2009Article
- Adult stem cells as a renewable source of insulin-producing cells.International journal of stem cells · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIn this study, we investigated the potential of umbilical cord blood stem cell lineages to produce C-peptide and insulin. MATERIALS AND
methodsLineage negative, CD133+ and CD34+ cells were analyzed by flow cytometry to assess expression of cell division antigens. These lineages were expanded in culture and subjected to an established protocol to differentiate mouse embryonic stem cells (ESCs) toward the pancreatic phenotype. Phase contrast and fluorescence immunocytochemistry were used to characterize differentiation markers with particular emphasis on insulin and C-peptide.
resultsAll 3 lineages expressed SSEA-4, a marker previously reported to be restricted to the ESC compartment. Phase contrast microscopy showed all three lineages recapitulated the treatment-dependent morphological changes of ESCs as well as the temporally restricted expression of nestin and vimentin during differentiation. After engineering, each isolate contained both C-peptide and insulin, a result also obtained following a much shorter protocol for ESCs.
conclusionsSince C-peptide can only be derived from de novo synthesis and processing of pre-proinsulin mRNA and protein, we conclude that these results are the first demonstration that human umbilical cord blood-derived stem cells can be engineered to engage in de novo synthesis of insulin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.